Nevertheless, PLK1 blockade cannot induce persisting regression of tumor, since the drug-treated vaccine stimulates a transient not a lasting DC activation (Fig. 4H) unless the vaccine is repeatedly administered. Here, PLK1 is linked to neoplasm.